- Home
- ONCO vs SNGX Comparison
ONCO vs SNGX Comparison
Compare ONCO & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCO
- SNGX
- Stock Information
- Founded
- ONCO 2018
- SNGX 1987
- Country
- ONCO United States
- SNGX United States
- Employees
- ONCO N/A
- SNGX N/A
- Industry
- ONCO Biotechnology: Pharmaceutical Preparations
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- ONCO Health Care
- SNGX Health Care
- Exchange
- ONCO Nasdaq
- SNGX Nasdaq
- Market Cap
- ONCO 1.8M
- SNGX 10.1M
- IPO Year
- ONCO 2022
- SNGX 1987
- Fundamental
- Price
- ONCO $3.00
- SNGX $2.76
- Analyst Decision
- ONCO
- SNGX Strong Buy
- Analyst Count
- ONCO 0
- SNGX 1
- Target Price
- ONCO N/A
- SNGX $6.00
- AVG Volume (30 Days)
- ONCO 46.7K
- SNGX 513.1K
- Earning Date
- ONCO 08-14-2025
- SNGX 11-07-2025
- Dividend Yield
- ONCO N/A
- SNGX N/A
- EPS Growth
- ONCO N/A
- SNGX N/A
- EPS
- ONCO N/A
- SNGX N/A
- Revenue
- ONCO $1,326,959.00
- SNGX N/A
- Revenue This Year
- ONCO N/A
- SNGX N/A
- Revenue Next Year
- ONCO N/A
- SNGX N/A
- P/E Ratio
- ONCO N/A
- SNGX N/A
- Revenue Growth
- ONCO N/A
- SNGX N/A
- 52 Week Low
- ONCO $2.61
- SNGX $1.09
- 52 Week High
- ONCO $552.50
- SNGX $6.23
- Technical
- Relative Strength Index (RSI)
- ONCO 47.80
- SNGX 48.33
- Support Level
- ONCO $3.00
- SNGX $2.58
- Resistance Level
- ONCO $3.32
- SNGX $2.98
- Average True Range (ATR)
- ONCO 0.16
- SNGX 0.18
- MACD
- ONCO 0.06
- SNGX -0.06
- Stochastic Oscillator
- ONCO 52.94
- SNGX 28.13
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).